Anti-trust continues to be an important legal area for businesses in China. In the last 12 months, we have seen revised measurements both locally and nationally, updated guidelines on drug prices and proposals to update IPR guidelines and stricter enforcement on merger control filing.
As we look ahead to the next 12 months, we expect to see more developments and more attention being given to competition activity in sectors including TMT, Life sciences & Healthcare, Utilities and Automotive.
We will be closely monitoring the developments and providing you with regular updates on them through our free eAlert service, Law-Now, and also WeChat ‘CMSAsia’.
For now, we hope you find our reflections and predictions of interest and help to your business as you plan for the year ahead.
If you would like to discuss any of the developments with us, please do let us know.